Značaj određivanja biomarkera resorpcije i stvaranja kostiju kod pacijenata sa krajnjim stadijumom bolesti bubrega
Significance of the determination of biomarkers of bone resorption and formation In patients with end-stage renal disease
Doktorska teza (Objavljena verzija)
Metapodaci
Prikaz svih podataka o dokumentuApstrakt
Vodiči za poboljšanje kvaliteta života i edukaciju pacijenata sa krajnjim stadijumom bolestibubrega (Kidney Disease Outcomes Quality Initiatives, KDOQI), objavljeni od strane američkeNacionalne Fondacije za bubreg (NKF) ukazuju na značaj biomarkera metabolizma kostiju kojebi trebalo određivati kod pacijenata sa krajnjim stadijumom bolesti bubrega (KSBB). PremaNKF pacijenti sa KSBB (stadijum 5) su oni čija je GFR ispod 15 mL/min/1,73 m2. To supredijalizni pacijenti, pacijenti koji su na terapiji hemodijalizom (HD) ili kontinuiranomambulatornom peritonealnom dijalizom (CAPD). Osnovni serumski biomarkeri koje bi trebaloodređivati kod svih pacijenata sa petim stadijumom bolesti bubrega su joni kalcijuma (Ca), jonineorganskog fosfata (P), joni magnezijuma (Mg), ukupna alkalna fosfataza (ALP), intaktniparatiroidni hormon (iPTH) i 25-hidroksi vitamin D (25D).Međutim, metabolizam kostiju najpouzdanije mogu da prikažu jedino biomarkeri koje stvarajućelije kostiju, osteoblasti i osteoklasti. Akt...ivnost osteoblasta, ćelija koje su odgovorne zastvaranje kostiju, najbolje odražavaju nivoi koštanog izoenzima alkalne fosfataze (BALP), kojije visoko specifičan za koštano tkivo. Aktivnost osteoklasta, ćelija koje su odgovorne zaresorpciju kostiju, specifično odražavaju nivoi tartarat rezistentne kisele fosfataze (TRAP).Dobar marker resorpcije kostiju jeste i beta-karboksi terminalni deo ukrštenih veza kolagena I,beta-CrossLaps (beta-CTx). Specifični serumski biomarkeri kostiju predstavljaju "biohemijskubiopsiju" značajnu za lakšu procenu i praćenje metabolizma kostiju.Cilj ovog rada bio je da se utvrdi značaj određivanja biomarkera resorpcije i stvaranja kostijukod KSBB pacijenata.Ispitivanjem je obuhvaćeno 40 predijaliznih pacijenata (18 žena i 22 muškarca) starosne dobi25−79, 114 pacijenata na CAPD (49 žena i 65 muškaraca) starosne dobi 30−84 i 112 pacijenatana HD (53 žene i 59 muškaraca) starosne dobi 25−79. Prosek trajanja lečenja hemodijalizombio je 76 meseci, dok su pacijenti na CAPD bili 35 meseci. Planirani biomarkeri formiranja iresorpcije kostiju su se određivali u serumu ispitivanih pacijenata na dan uzorkovanja i to kodpredijaliznih i CAPD pacijenata kada su dolazili na rutinske kontrolne preglede, a kodpacijenata na HD neposredno pre terapije dijalizom. Radi određivanja referentnih intervala userumu, analizirani biomarkeri su određivani i u grupi od 50 zdravih dobrovoljaca (25 žena i 25muškaraca) starosne dobi od 20−70 godina.ALP, TRAP, Ca, P i Mg su određeni fotometrijski (Olympus AU2700 ISE). BALP je određenzonskom elektroforezom (Sebia Hydrasis), beta-CTx i iPTH su određeni ECLIA metodom(Rosche Elecsys), a 25D HPLC-om reverznih faza (ChromLineR Clinical HPLC softwareVersion 4.20).Određivanje analiziranih biomarkera u serumu se smatralo pouzdanim na osnovu koeficijenatavarijacije dobijenih testiranjem preciznosti u seriji (Kv: 0,6%−3,3%) i iz dana u dan (Kv:1,0%−3,6%).Ustanovljena je normalna raspodela vrednosti za svaki od analiziranih biomarkera kodpredijaliznih, HD i CAPD pacijenata. Kod sve tri ispitivane grupe pacijenata uočen je uticajpola na vrednosti iPTH, kao i na vrednosti neorganskog fosfata kod HD pacijenata i navrednosti CaxP kod CAPD pacijenata. Međutim, uticaj starosti je kod sve tri grupe pacijenatauočen jedino na vrednosti BALP. Takođe, dužina trajanja HD imala je uticaj na vrednosti ALP BALP, a CAPD samo na vrednosti jona magnezijuma...
Guidelines for improving the quality of life and education of patients with end-stage renaldisease (Kidney Disease Outcomes Quality Initiatives, KDOQI), published by the U.S.National Kidney Foundation (NKF), indicate the importance of biomarkers of bone metabolismthat should be determined in patients with end-stage renal disease (ESRD). According to theNKF, ESRD patients (stage 5) are those with a GFR below 15 ml/min/1.73 m2. These arepredialysis patients, patients who are treated with hemodialysis (HD) or continuous ambulatoryperitoneal dialysis (CAPD). The basic serum biomarkers that could be determined in allpatients with the fifth stage renal disease are: calcium ions (Ca), inorganic phosphate ions (P),magnesium ions (Mg), the total alkaline phosphatase (ALP), an intact parathyroid hormone(iPTH) and 25-hydroxy vitamin D (25D).However, the most reliable bone metabolism can be represented only by biomarker created bybone cells, osteoblasts and osteoclasts. The activity of osteoblasts..., the cells responsible for boneformation, is well expressed by the levels of bone alkaline phosphatase isoenzymes (BALP),which is highly specific for bone tissue. The activity of osteoclasts, the cells responsible forbone resorption, specifically reflect levels of tartrate resistant acid phosphatase (TRAP). Agood marker of bone resorption is the beta-carboxy terminal telopeptide of collagen type I,beta-CrossLaps (beta-CTx). Specific serum biomarkers of bone are "biochemical biopsy"important to facilitate the assessment and monitoring of bone metabolism.The aim of this study was to assess the usefulness of biomarkers of bone resorption and boneformation in ESRD patients.The study included 40 predialysis patients (18 women and 22 men) aged 25−79, 114 patients onCAPD (49 women and 65 men) aged 30−84 and 112 patients on HD (53 women and 59 men)aged 25−79. Average duration of the hemodialysis treatment was 76 months, while patients onCAPD treated 35 months. The analysed biomarkers of bone formation and resorption weredetermined in the serum of patients on the day of sampling and in predialysis patients and inpatients on CAPD when they came to the routine check-ups, and in patients on HD immediatelybefore dialysis therapy. To determine the reference intervals, analyzed biomarkers weremeasured in a group of 50 healthy volunteers (25 women and 25 men) aged 20−70 years.ALP, TRAP, Ca, P and Mg were determined photometrically (Olympus AU2700 ISE). BALPvalues were determined with zone electrophoresis (SEBIA Hydrasis), beta-CTx and iPTHvalues were determined with ECLIA (Elecsys Rosche) and 25D values were detrmined byHPLC with reversed phase detection (HPLC ChromLineR Clinical software Version 4:20).Determination of the analysed biomarkers is considered reliable based on the coefficients ofvariation obtained by precision testing in the series (Cv: 0.6%−3.3%) and from day to day (Cv:1.0%−3.6%).We established the normal distribution of the values for each of the analysed biomarkers inpredialysis and dialysed patients. There were different values of iPTH, P and CaxP levels in theall analysed groups according to gender. However, the effect of age was observed only on thevalues of BALP. Duration of the dialysis had impact only on the values of ALP and BALP inHD patients and on Mg levels in CAPD patients...
Ključne reči:
koštani izoenzim alkalne fosfataze / bone isoenzyme of alkaline phosphatase / tartrate resistant acid phosphatase / beta-CTx / vitamin D / end stage renal disease / tartarat rezistentna kisela fosfataza / beta-CTx / vitamin D / krajnji stadijum bolesti bubregaIzvor:
Универзитет у Београду, 2014Izdavač:
- Универзитет у Београду, Фармацеутски факултет
URI
http://eteze.bg.ac.rs/application/showtheses?thesesId=1782https://fedorabg.bg.ac.rs/fedora/get/o:9435/bdef:Content/download
http://vbs.rs/scripts/cobiss?command=DISPLAY&base=70036&RID=46632975
http://nardus.mpn.gov.rs/123456789/3169
https://farfar.pharmacy.bg.ac.rs/handle/123456789/3399
Kolekcije
Institucija/grupa
PharmacyTY - THES AU - Milinković, Neda PY - 2014 UR - http://eteze.bg.ac.rs/application/showtheses?thesesId=1782 UR - https://fedorabg.bg.ac.rs/fedora/get/o:9435/bdef:Content/download UR - http://vbs.rs/scripts/cobiss?command=DISPLAY&base=70036&RID=46632975 UR - http://nardus.mpn.gov.rs/123456789/3169 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3399 AB - Vodiči za poboljšanje kvaliteta života i edukaciju pacijenata sa krajnjim stadijumom bolestibubrega (Kidney Disease Outcomes Quality Initiatives, KDOQI), objavljeni od strane američkeNacionalne Fondacije za bubreg (NKF) ukazuju na značaj biomarkera metabolizma kostiju kojebi trebalo određivati kod pacijenata sa krajnjim stadijumom bolesti bubrega (KSBB). PremaNKF pacijenti sa KSBB (stadijum 5) su oni čija je GFR ispod 15 mL/min/1,73 m2. To supredijalizni pacijenti, pacijenti koji su na terapiji hemodijalizom (HD) ili kontinuiranomambulatornom peritonealnom dijalizom (CAPD). Osnovni serumski biomarkeri koje bi trebaloodređivati kod svih pacijenata sa petim stadijumom bolesti bubrega su joni kalcijuma (Ca), jonineorganskog fosfata (P), joni magnezijuma (Mg), ukupna alkalna fosfataza (ALP), intaktniparatiroidni hormon (iPTH) i 25-hidroksi vitamin D (25D).Međutim, metabolizam kostiju najpouzdanije mogu da prikažu jedino biomarkeri koje stvarajućelije kostiju, osteoblasti i osteoklasti. Aktivnost osteoblasta, ćelija koje su odgovorne zastvaranje kostiju, najbolje odražavaju nivoi koštanog izoenzima alkalne fosfataze (BALP), kojije visoko specifičan za koštano tkivo. Aktivnost osteoklasta, ćelija koje su odgovorne zaresorpciju kostiju, specifično odražavaju nivoi tartarat rezistentne kisele fosfataze (TRAP).Dobar marker resorpcije kostiju jeste i beta-karboksi terminalni deo ukrštenih veza kolagena I,beta-CrossLaps (beta-CTx). Specifični serumski biomarkeri kostiju predstavljaju "biohemijskubiopsiju" značajnu za lakšu procenu i praćenje metabolizma kostiju.Cilj ovog rada bio je da se utvrdi značaj određivanja biomarkera resorpcije i stvaranja kostijukod KSBB pacijenata.Ispitivanjem je obuhvaćeno 40 predijaliznih pacijenata (18 žena i 22 muškarca) starosne dobi25−79, 114 pacijenata na CAPD (49 žena i 65 muškaraca) starosne dobi 30−84 i 112 pacijenatana HD (53 žene i 59 muškaraca) starosne dobi 25−79. Prosek trajanja lečenja hemodijalizombio je 76 meseci, dok su pacijenti na CAPD bili 35 meseci. Planirani biomarkeri formiranja iresorpcije kostiju su se određivali u serumu ispitivanih pacijenata na dan uzorkovanja i to kodpredijaliznih i CAPD pacijenata kada su dolazili na rutinske kontrolne preglede, a kodpacijenata na HD neposredno pre terapije dijalizom. Radi određivanja referentnih intervala userumu, analizirani biomarkeri su određivani i u grupi od 50 zdravih dobrovoljaca (25 žena i 25muškaraca) starosne dobi od 20−70 godina.ALP, TRAP, Ca, P i Mg su određeni fotometrijski (Olympus AU2700 ISE). BALP je određenzonskom elektroforezom (Sebia Hydrasis), beta-CTx i iPTH su određeni ECLIA metodom(Rosche Elecsys), a 25D HPLC-om reverznih faza (ChromLineR Clinical HPLC softwareVersion 4.20).Određivanje analiziranih biomarkera u serumu se smatralo pouzdanim na osnovu koeficijenatavarijacije dobijenih testiranjem preciznosti u seriji (Kv: 0,6%−3,3%) i iz dana u dan (Kv:1,0%−3,6%).Ustanovljena je normalna raspodela vrednosti za svaki od analiziranih biomarkera kodpredijaliznih, HD i CAPD pacijenata. Kod sve tri ispitivane grupe pacijenata uočen je uticajpola na vrednosti iPTH, kao i na vrednosti neorganskog fosfata kod HD pacijenata i navrednosti CaxP kod CAPD pacijenata. Međutim, uticaj starosti je kod sve tri grupe pacijenatauočen jedino na vrednosti BALP. Takođe, dužina trajanja HD imala je uticaj na vrednosti ALP BALP, a CAPD samo na vrednosti jona magnezijuma... AB - Guidelines for improving the quality of life and education of patients with end-stage renaldisease (Kidney Disease Outcomes Quality Initiatives, KDOQI), published by the U.S.National Kidney Foundation (NKF), indicate the importance of biomarkers of bone metabolismthat should be determined in patients with end-stage renal disease (ESRD). According to theNKF, ESRD patients (stage 5) are those with a GFR below 15 ml/min/1.73 m2. These arepredialysis patients, patients who are treated with hemodialysis (HD) or continuous ambulatoryperitoneal dialysis (CAPD). The basic serum biomarkers that could be determined in allpatients with the fifth stage renal disease are: calcium ions (Ca), inorganic phosphate ions (P),magnesium ions (Mg), the total alkaline phosphatase (ALP), an intact parathyroid hormone(iPTH) and 25-hydroxy vitamin D (25D).However, the most reliable bone metabolism can be represented only by biomarker created bybone cells, osteoblasts and osteoclasts. The activity of osteoblasts, the cells responsible for boneformation, is well expressed by the levels of bone alkaline phosphatase isoenzymes (BALP),which is highly specific for bone tissue. The activity of osteoclasts, the cells responsible forbone resorption, specifically reflect levels of tartrate resistant acid phosphatase (TRAP). Agood marker of bone resorption is the beta-carboxy terminal telopeptide of collagen type I,beta-CrossLaps (beta-CTx). Specific serum biomarkers of bone are "biochemical biopsy"important to facilitate the assessment and monitoring of bone metabolism.The aim of this study was to assess the usefulness of biomarkers of bone resorption and boneformation in ESRD patients.The study included 40 predialysis patients (18 women and 22 men) aged 25−79, 114 patients onCAPD (49 women and 65 men) aged 30−84 and 112 patients on HD (53 women and 59 men)aged 25−79. Average duration of the hemodialysis treatment was 76 months, while patients onCAPD treated 35 months. The analysed biomarkers of bone formation and resorption weredetermined in the serum of patients on the day of sampling and in predialysis patients and inpatients on CAPD when they came to the routine check-ups, and in patients on HD immediatelybefore dialysis therapy. To determine the reference intervals, analyzed biomarkers weremeasured in a group of 50 healthy volunteers (25 women and 25 men) aged 20−70 years.ALP, TRAP, Ca, P and Mg were determined photometrically (Olympus AU2700 ISE). BALPvalues were determined with zone electrophoresis (SEBIA Hydrasis), beta-CTx and iPTHvalues were determined with ECLIA (Elecsys Rosche) and 25D values were detrmined byHPLC with reversed phase detection (HPLC ChromLineR Clinical software Version 4:20).Determination of the analysed biomarkers is considered reliable based on the coefficients ofvariation obtained by precision testing in the series (Cv: 0.6%−3.3%) and from day to day (Cv:1.0%−3.6%).We established the normal distribution of the values for each of the analysed biomarkers inpredialysis and dialysed patients. There were different values of iPTH, P and CaxP levels in theall analysed groups according to gender. However, the effect of age was observed only on thevalues of BALP. Duration of the dialysis had impact only on the values of ALP and BALP inHD patients and on Mg levels in CAPD patients... PB - Универзитет у Београду, Фармацеутски факултет T2 - Универзитет у Београду T1 - Značaj određivanja biomarkera resorpcije i stvaranja kostiju kod pacijenata sa krajnjim stadijumom bolesti bubrega T1 - Significance of the determination of biomarkers of bone resorption and formation In patients with end-stage renal disease UR - https://hdl.handle.net/21.15107/rcub_nardus_3169 ER -
@phdthesis{ author = "Milinković, Neda", year = "2014", abstract = "Vodiči za poboljšanje kvaliteta života i edukaciju pacijenata sa krajnjim stadijumom bolestibubrega (Kidney Disease Outcomes Quality Initiatives, KDOQI), objavljeni od strane američkeNacionalne Fondacije za bubreg (NKF) ukazuju na značaj biomarkera metabolizma kostiju kojebi trebalo određivati kod pacijenata sa krajnjim stadijumom bolesti bubrega (KSBB). PremaNKF pacijenti sa KSBB (stadijum 5) su oni čija je GFR ispod 15 mL/min/1,73 m2. To supredijalizni pacijenti, pacijenti koji su na terapiji hemodijalizom (HD) ili kontinuiranomambulatornom peritonealnom dijalizom (CAPD). Osnovni serumski biomarkeri koje bi trebaloodređivati kod svih pacijenata sa petim stadijumom bolesti bubrega su joni kalcijuma (Ca), jonineorganskog fosfata (P), joni magnezijuma (Mg), ukupna alkalna fosfataza (ALP), intaktniparatiroidni hormon (iPTH) i 25-hidroksi vitamin D (25D).Međutim, metabolizam kostiju najpouzdanije mogu da prikažu jedino biomarkeri koje stvarajućelije kostiju, osteoblasti i osteoklasti. Aktivnost osteoblasta, ćelija koje su odgovorne zastvaranje kostiju, najbolje odražavaju nivoi koštanog izoenzima alkalne fosfataze (BALP), kojije visoko specifičan za koštano tkivo. Aktivnost osteoklasta, ćelija koje su odgovorne zaresorpciju kostiju, specifično odražavaju nivoi tartarat rezistentne kisele fosfataze (TRAP).Dobar marker resorpcije kostiju jeste i beta-karboksi terminalni deo ukrštenih veza kolagena I,beta-CrossLaps (beta-CTx). Specifični serumski biomarkeri kostiju predstavljaju "biohemijskubiopsiju" značajnu za lakšu procenu i praćenje metabolizma kostiju.Cilj ovog rada bio je da se utvrdi značaj određivanja biomarkera resorpcije i stvaranja kostijukod KSBB pacijenata.Ispitivanjem je obuhvaćeno 40 predijaliznih pacijenata (18 žena i 22 muškarca) starosne dobi25−79, 114 pacijenata na CAPD (49 žena i 65 muškaraca) starosne dobi 30−84 i 112 pacijenatana HD (53 žene i 59 muškaraca) starosne dobi 25−79. Prosek trajanja lečenja hemodijalizombio je 76 meseci, dok su pacijenti na CAPD bili 35 meseci. Planirani biomarkeri formiranja iresorpcije kostiju su se određivali u serumu ispitivanih pacijenata na dan uzorkovanja i to kodpredijaliznih i CAPD pacijenata kada su dolazili na rutinske kontrolne preglede, a kodpacijenata na HD neposredno pre terapije dijalizom. Radi određivanja referentnih intervala userumu, analizirani biomarkeri su određivani i u grupi od 50 zdravih dobrovoljaca (25 žena i 25muškaraca) starosne dobi od 20−70 godina.ALP, TRAP, Ca, P i Mg su određeni fotometrijski (Olympus AU2700 ISE). BALP je određenzonskom elektroforezom (Sebia Hydrasis), beta-CTx i iPTH su određeni ECLIA metodom(Rosche Elecsys), a 25D HPLC-om reverznih faza (ChromLineR Clinical HPLC softwareVersion 4.20).Određivanje analiziranih biomarkera u serumu se smatralo pouzdanim na osnovu koeficijenatavarijacije dobijenih testiranjem preciznosti u seriji (Kv: 0,6%−3,3%) i iz dana u dan (Kv:1,0%−3,6%).Ustanovljena je normalna raspodela vrednosti za svaki od analiziranih biomarkera kodpredijaliznih, HD i CAPD pacijenata. Kod sve tri ispitivane grupe pacijenata uočen je uticajpola na vrednosti iPTH, kao i na vrednosti neorganskog fosfata kod HD pacijenata i navrednosti CaxP kod CAPD pacijenata. Međutim, uticaj starosti je kod sve tri grupe pacijenatauočen jedino na vrednosti BALP. Takođe, dužina trajanja HD imala je uticaj na vrednosti ALP BALP, a CAPD samo na vrednosti jona magnezijuma..., Guidelines for improving the quality of life and education of patients with end-stage renaldisease (Kidney Disease Outcomes Quality Initiatives, KDOQI), published by the U.S.National Kidney Foundation (NKF), indicate the importance of biomarkers of bone metabolismthat should be determined in patients with end-stage renal disease (ESRD). According to theNKF, ESRD patients (stage 5) are those with a GFR below 15 ml/min/1.73 m2. These arepredialysis patients, patients who are treated with hemodialysis (HD) or continuous ambulatoryperitoneal dialysis (CAPD). The basic serum biomarkers that could be determined in allpatients with the fifth stage renal disease are: calcium ions (Ca), inorganic phosphate ions (P),magnesium ions (Mg), the total alkaline phosphatase (ALP), an intact parathyroid hormone(iPTH) and 25-hydroxy vitamin D (25D).However, the most reliable bone metabolism can be represented only by biomarker created bybone cells, osteoblasts and osteoclasts. The activity of osteoblasts, the cells responsible for boneformation, is well expressed by the levels of bone alkaline phosphatase isoenzymes (BALP),which is highly specific for bone tissue. The activity of osteoclasts, the cells responsible forbone resorption, specifically reflect levels of tartrate resistant acid phosphatase (TRAP). Agood marker of bone resorption is the beta-carboxy terminal telopeptide of collagen type I,beta-CrossLaps (beta-CTx). Specific serum biomarkers of bone are "biochemical biopsy"important to facilitate the assessment and monitoring of bone metabolism.The aim of this study was to assess the usefulness of biomarkers of bone resorption and boneformation in ESRD patients.The study included 40 predialysis patients (18 women and 22 men) aged 25−79, 114 patients onCAPD (49 women and 65 men) aged 30−84 and 112 patients on HD (53 women and 59 men)aged 25−79. Average duration of the hemodialysis treatment was 76 months, while patients onCAPD treated 35 months. The analysed biomarkers of bone formation and resorption weredetermined in the serum of patients on the day of sampling and in predialysis patients and inpatients on CAPD when they came to the routine check-ups, and in patients on HD immediatelybefore dialysis therapy. To determine the reference intervals, analyzed biomarkers weremeasured in a group of 50 healthy volunteers (25 women and 25 men) aged 20−70 years.ALP, TRAP, Ca, P and Mg were determined photometrically (Olympus AU2700 ISE). BALPvalues were determined with zone electrophoresis (SEBIA Hydrasis), beta-CTx and iPTHvalues were determined with ECLIA (Elecsys Rosche) and 25D values were detrmined byHPLC with reversed phase detection (HPLC ChromLineR Clinical software Version 4:20).Determination of the analysed biomarkers is considered reliable based on the coefficients ofvariation obtained by precision testing in the series (Cv: 0.6%−3.3%) and from day to day (Cv:1.0%−3.6%).We established the normal distribution of the values for each of the analysed biomarkers inpredialysis and dialysed patients. There were different values of iPTH, P and CaxP levels in theall analysed groups according to gender. However, the effect of age was observed only on thevalues of BALP. Duration of the dialysis had impact only on the values of ALP and BALP inHD patients and on Mg levels in CAPD patients...", publisher = "Универзитет у Београду, Фармацеутски факултет", journal = "Универзитет у Београду", title = "Značaj određivanja biomarkera resorpcije i stvaranja kostiju kod pacijenata sa krajnjim stadijumom bolesti bubrega, Significance of the determination of biomarkers of bone resorption and formation In patients with end-stage renal disease", url = "https://hdl.handle.net/21.15107/rcub_nardus_3169" }
Milinković, N.. (2014). Značaj određivanja biomarkera resorpcije i stvaranja kostiju kod pacijenata sa krajnjim stadijumom bolesti bubrega. in Универзитет у Београду Универзитет у Београду, Фармацеутски факултет.. https://hdl.handle.net/21.15107/rcub_nardus_3169
Milinković N. Značaj određivanja biomarkera resorpcije i stvaranja kostiju kod pacijenata sa krajnjim stadijumom bolesti bubrega. in Универзитет у Београду. 2014;. https://hdl.handle.net/21.15107/rcub_nardus_3169 .
Milinković, Neda, "Značaj određivanja biomarkera resorpcije i stvaranja kostiju kod pacijenata sa krajnjim stadijumom bolesti bubrega" in Универзитет у Београду (2014), https://hdl.handle.net/21.15107/rcub_nardus_3169 .